GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

51

SBRT for Extensive Macrovascular Invasion in HCC- J Hepatol Feb.26

Macrovascular invasion (MVI) in hepatocellular carcinoma (HCC), particularly involving the hepatic veins, inferior vena cava, or right atrium, is associated with extremely poor prognosis and limited treatment options....

52

Neoadjuvant Nivolumab–Ipilimumab in Resectable HCC- J Hepatol Feb.26

Immune checkpoint inhibitors have transformed the treatment of advanced hepatocellular carcinoma (HCC), but their role in potentially resectable disease remains under active investigation. This single-arm study evaluated nivolumab...

53

Lenvatinib After Atezolizumab–Bevacizumab Failure in Advanced HCC- J Hepatol Feb.26

Atezolizumab plus bevacizumab is the established first-line treatment for unresectable hepatocellular carcinoma (HCC). However, most patients eventually progress, and the optimal second-line therapy after atezo-bev failure remains uncertain,...

54

HBV Reactivation Risk With ICIs vs TKIs in Liver Cancer

Hepatitis B virus (HBV) reactivation is a recognized risk during systemic therapy for liver cancer, particularly in high-endemic regions where HBV is a leading cause of hepatocellular carcinoma...

55

CARES-009 phase 2/3 trial

The CARES-009 phase 2/3 trial investigated the efficacy of perioperative camrelizumab plus rivoceranib in patients with hepatocellular carcinoma (HCC) at intermediate or high risk of relapse. The trial...

56

Recurrent HCC followingTACE

Recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE) is a significant clinical challenge. TACE is widely used as a treatment modality for HCC, particularly for patients with intermediate-stage...

57

Nutrition in Hepatocellular Carcinoma - J of JGH - Jan,26

The topic of nutrition in hepatocellular carcinoma (HCC) is highly relevant and extensively studied due to the profound impact of malnutrition on patient outcomes. While I cannot access...

58

Engineered T-Cell Therapy and HCC - J of Hepatology. Jan 26

Engineered T-cell therapy is a precision immunotherapy approach designed to treat cancer by modifying a patient's T cells to enhance their ability to target and destroy cancer cells....

59

Serum N-Glycomics analysis and HBV - Hepatology Jan.2026

Serum N-glycomics analysis refers to the study of N-linked glycans (complex sugar molecules attached to proteins) present in serum. This analytical approach focuses on profiling and identifying specific...

60

HCC risk in PSC (Hepatology Jan. 26)

Introduction: Primary sclerosing cholangitis (PSC) is a chronic liver disease that can lead to complications, including hepatocellular carcinoma (HCC). However, the actual risk of developing HCC in PSC...

Previous
15678
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer